Quantitative MR imaging of study of intravitreal sustained release of VEGF in rabbits

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 6, 2000, Pages 1561-1569

  Alikacem, Nadir ^a,d   Yosbizawa, Toyobisa ^a,b   Nelson, Kevin D ^c   Wilson, Charles A ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b NIIGATA UNIVERSITY   (Japan)

^c UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOFOSVESET; POLYMER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RABBIT; RETINA;

ANIMALS; BLOOD-RETINAL BARRIER; CONTRAST MEDIA; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; ENDOTHELIAL GROWTH FACTORS; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; LACTIC ACID; LYMPHOKINES; MAGNETIC RESONANCE IMAGING; MALE; POLYGLYCOLIC ACID; POLYMERS; RABBITS; RETINA; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITREOUS BODY;

EID: 0034018441     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sone H, Kawakami Y, Okuda Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia. 1997;40:726-730.
2. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13:18-32.
3. Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993;12:3033-3024.
4. Aiello LP, Avery RL, Arrigg PG. et al. Vascular endothelial growth factor in ocular fluid of patients with DR and other retinal disorders [see comments]. N Engl J Med. 1994;331:1480-1487.
5. Hammes HP, Lin J, Bretzel RG, et al. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998;47:40140-146.
6. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
7. Clermont AC, Aiello LP, Mori F, et al. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy [see comments]. Am J Ophthalmol. 1997; 124:433-446.
8. Gerhardinger C, Brown LF, Roy S, et al. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol. 1998;152:1453-1462.
9. Miyamoto K, Ogura Y, Nishiwaki H, et al. Evaluation of retinal microcirculatory alterations in the Goto-Kakizaki rat. A spontaneous model of non-insulin-dependent diabetes. Invest Ophthalmol Vis Sci. 1996;37:898-905.
10. Guerrin M, Moukadiri H, Chollet P, et al. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol. 1995;164:385-394.
11. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-1544.
12. Murata T, Nagai R, Ishibashi T, et al. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997;40:764-769.
13. Thieme H, Aiello LP, Takagi H, et al. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 1995;44:98-103.
14. Ozaki H, Hayashi H, Vinores SA, et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997;64:505-517.
15. Gadian DG, Payne JA, Bryant DJ, et al. Gadolinium DTPA as a contrast agent in MR imaging - theoretical projections and practical observations. J Comput Assist Tomogr. 1985;9:242-251.
16. Sze G. New applications of MR contrast agents in neuroradiology. Neuroradiology. 1990;32:421-438.
17. Berkowitz BA, Sato Y, Wilson CA, de Juan E. Blood-retinal barrier breakdown investigated by real-time magnetic resonance imaging after gadolinium-diethylenetriaminepentaacetic acid injection. Invest Ophthalmol Vis Sci. 1991;32:2854-2860.
18. Berkowitz BA, Tofts PS, Sen HA, et al. Accurate and precise measurement of blood-retinal barrier breakdown using dynamic Gd-DTPA MRI. Invest Ophthalmol Vis Sci. 1992;33:3500-3506.
19. Tofts PS, Berkowitz BA. Measurement of capillary permeability from the Gd enhancement curve: a comparison of bolus and constant infusion injection methods. Magn Reson Imaging. 1994; 12:81-91.
20. Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: albumin-targeted contrast agent for MR angiography. Radiology. 1998;207: 529-538.
21. Parmelee DJ, Walovitch RC, Ouellet HS, Lauffer RB. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol. 1997;32:741-747.
22. Wilson CA, Fleckenstein JL, Berkowitz BA, Green ME. Preretinal neovascularization in diabetic retinopathy: a preliminary investigation using contrast-enhanced magnetic resonance imaging. J Diabetes Complications. 1992;6:223-229.
23. Wood GK, Berkowitz BA, Wilson CA. Visualization of subtle contrast-related intensity changes using temporal correlation. Magn Reson Imaging. 1994;12:101310-101320.
24. Vinores SA, Derevjanik NL, Mahlow J, et al. Electron microscopic evidence of the mechanics of blood-retinal barrier breakdown in diabetic rabbits: comparison with magnetic resonance imaging Pathol Res Pract 1998;194:497-505.
25. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17:357-367.
26. Wilson CA, Berkowitz BA, Funatsu H, et al. Blood-retinal barrier breakdown following experimental retinal ischemia and reperfusion. Exp Eye Res. 1995;61:547-557.
27. Luna JD, Chan CC, Derevjanik NL, et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. JNeurosci Res. 1997;49:268-280.
28. Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy. Br J Ophthalmol. 1998;82:561-568.
29. Mathews MK, Merges C, McLeod DS. Lutty GA. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:2729-2741.
30. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol. 1997;12:99-109.
31. Tofts PS, Kermode AG. Measurements of blood-brain barrier permeability and leakage space using dynamic MR imaging. Magn Reson Med. 1991;17:357-367.
32. Yang L, Fassihi R. Zero-order release kinetics from a self-correcting floatable asymmetric configuration drug delivery system. J Pharm Sci. 1996;85:170-173.